Novartis to answer U.S. Senate demand for data manipulation details

诺华( Novartis )回应美国参议院对数据操纵细节的要求

2019-08-19 15:20:41 YAHOO!FINANCE

本文共344个字,阅读需1分钟

ZURICH - Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval. "We are planning to respond but we haven't submitted yet," a spokesman said on Monday. U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.  Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation. (Reporting by John Miller)
ZURICH-Novartis < NOVN 。一位美国参议员要求提供有关其基因治疗佐尔甘斯曼( Zolgensma )相关数据操纵的细节,美国计划对这位瑞士制药商决定推迟通知监管机构,直到该治疗获得批准。 “我们计划作出回应,但尚未提交,”一位发言人周一说。 美国参议院财政委员会主席 ChuckGrassley 要求这家总部位于巴塞尔的公司在8月23日之前提供其210万美元的基因疗法治疗脊柱肌肉萎缩的数据操作细节。 诺华( Novartis )已在一项内部调查中终止了数名科学家的职务。该公司在5月份获得了佐尔甘斯曼的批准,比该公司向美国食品药品监督管理局(Food and Drug Administration)( FDA )通报涉嫌数据欺诈的一个多月前。 (约翰·米勒的报告)

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文